Interventional Oncology Global Market – Forecast to 2029

Publishing Date : September, 2022
Report Code : HCMD0168
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Note: The report would be dispatched after confirmation of payment

Interventional Oncology (IO) is a rapidly growing field in cancer care that uses minimally invasive procedures performed under image guidance to diagnose and treat patients with liver, kidney, lung, Brain & Spine, prostate, and other cancers. Rather than removing tumors through open surgical procedures, these image-guided procedures can be performed in place of or in combination with other cancer treatments to provide truly comprehensive care. The advantage of these methods is that IO has much less effect on the body compared to conventional procedures.

 According to IQ4I analysis, the interventional oncology global market is expected to grow at a high single from 2022 to 2029. Some of the factors driving the market are the increasing prevalence of cancer cases, the increasing geriatric population and the growing adoption of minimally invasive procedures. Factors such as technological advancements in the field of interventional oncology and expansion in emerging markets are opportunities for the market. Similarly, side effects and risks associated with the use, lack of awareness, and lack of trained professionals are restraining the market growth, While, the availability of alternative treatments and stringent regulatory guidelines are a threat to market growth.

The interventional oncology market is segmented based on products, applications, end-users, and geography. The interventional oncology market based on products is segmented as ablation and embolization. The embolization segment is expected to grow at a mid-single from 2022 to 2029. The ablation segment is the fastest-growing double digit from 2022 to 2029.

Ablation global market based on product type is sub-segmented into radiofrequency ablation, microwave ablation, Cryoablation, HIFU, and others (irreversible electroporation and MRI-guided laser ablation). Among these, microwave ablation is expected to grow at a double-digit from 2022 to 2029. The HIFU segment is the fastest-growing in high teens from 2022. Embolization global market based on procedure is sub-segmented into trans-arterial radioembolization (TARE)/selective internal radiation therapy (SIRT), trans-arterial chemo-embolization (TACE), drug-eluting beads trans-arterial chemo-embolization (DEB-TACE) and trans-arterial embolization (TAE)/bland embolization.  Among procedures, TARE/SIRT is expected to grow at a mid-single from 2022 to 2029. The Bland/TAE is the fastest-growing at mid-single from 2022 to 2029.

Interventional oncology global market based on application is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others. Among these applications, the liver cancer segment is expected to grow at mid-single from 2022 to 2029. Brain & spine cancer is the fastest-growing at double-digit from 2022. Further, the application market is sub-segmented into ablation and embolization applications.

The ablation market is segmented into liver cancer, kidney cancer, lung cancer, brain & spine cancer, prostate cancer, and others. Among these applications, the liver cancer segment is expected to grow double-digit from 2022 to 2029. Brain & spine cancer is the fastest-growing segment with a double-digit from 2022 to 2029.

Embolization global market based on application is segmented into liver cancer, lung cancer, prostate cancer, and others. Among embolization applications, the liver cancer segment is expected to grow at mid-single from 2022 to 2029.

The interventional Oncology global market by end-users is segmented into hospitals, ambulatory surgical centers (ASC), and academics & research institutes. Among end-users, the hospital is expected to grow at a high single from 2022 to 2029. The ambulatory surgical center is the fastest-growing at a high single from 2022 to 2029.

The interventional oncology market by region is segmented as North America (U.S. and Rest of North America), Europe (Germany, France, Italy, and Rest of Europe), Asia-Pacific (China, Japan, Australia, and Rest of APAC), and the Rest of the world (Brazil, Rest of LATAM and the Middle East & Others). North America is expected to be at a high single from 2022 to 2029. Mainly due to increasing incidences of cancer, increasing demand for minimally invasive surgeries, favorable reimbursements, product launches, and availability of skilled personnel. The Asia-Pacific is the fastest-growing region with a double-digit from 2022 to 2020. Due to the increasing geriatric population and increasing incidence of cancer, increased expenditure on healthcare facilities, increasing awareness about interventional oncology, and low-cost surgery is driving the market.

The interventional oncology global market is a consolidated market with the top 6 players occupying a major share of the market hence all the existing players in this market are involved in developing new and advanced therapeutics to maintain their market shares. Some of the major players in the interventional oncology market include Medtronic Plc (Ireland), Sirtex Medical (China), Boston Scientific Corporation (U.S.), Angiodynamics (U.S.), Guerbet (France), Merit Medical System (U.S.), Siemens healthineers, Inc. (Varian) (Germany.), Terumo Corporation (Japan), Johnson & Johnson (U.S.), AngioDynamics, Inc. (U.S.), and Monteris Medical (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • The U.S.
  • Rest of North America
  • Europe
  • Germany
  • France
  • Italy
  • Rest of Europe
  • Asia-Pacific 
  • Japan
  • China
  • Australia
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Rest of LATAM
  • The Middle East and Others
  •  

  • 1     EXECUTIVE SUMMARY
  • 2     INTRODUCTION
    • 2.1     KEY TAKEAWAYS
    • 2.2     SCOPE OF THE REPORT
    • 2.3     REPORT DESCRIPTION
    • 2.4     MARKETS COVERED
    • 2.5     STAKEHOLDERS
    • 2.6     RESEARCH METHODOLOGY
      • 2.6.1     MARKET SIZE ESTIMATION
      • 2.6.2     MARKET BREAKDOWN AND DATA TRIANGULATION
      • 2.6.3     SECONDARY SOURCES
      • 2.6.4     PRIMARY SOURCES
      • 2.6.5     KEY DATA POINTS FROM SECONDARY SOURCES
      • 2.6.6     KEY DATA POINTS FROM PRIMARY SOURCES
      • 2.6.7     ASSUMPTIONS
  • 3     MARKET ANALYSIS
    • 3.1     INTRODUCTION
    • 3.2     MARKET SEGMENTATION
    • 3.3     FACTORS INFLUENCING MARKET
      • 3.3.1     DRIVERS AND OPPORTUNITIES
        • 3.3.1.1     INCREASING INCIDENCE OF CANCER CASES
        • 3.3.1.2     GROWING ADOPTION OF MINIMALLY INVASIVE PROCEDURES
        • 3.3.1.3     INCREASING GERIATRIC POPULATION
        • 3.3.1.4     TECHNOLOGICAL ADVANCEMENTS IN THE FIELD OF INTERVENTIONAL ONCOLOGY
        • 3.3.1.5     EXPANSION IN THE EMERGING MARKETS
      • 3.3.2     RESTRAINTS AND THREATS
        • 3.3.2.1     SIDE EFFECTS AND RISKS ASSOCIATED WITH THE USE
        • 3.3.2.2     LACK OF AWARENESS
        • 3.3.2.3     LACK OF TRAINED PROFESSIONALS
        • 3.3.2.4     AVAILABILITY OF ALTERNATIVE TREATMENTS
        • 3.3.2.5     STRINGENT REGULATORY GUIDELINES
    • 3.4     REGULATORY AFFAIRS
      • 3.4.1     INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
        • 3.4.1.1     ISO 9001: 2015 QUALITY MANAGEMENT SYSTEM
        • 3.4.1.2     ISO:13485 MEDICAL DEVICES
        • 3.4.1.3     ISO 10993 BIOLOGICAL EVALUATION OF MEDICAL DEVICES
        • 3.4.1.4     ISO 14971 RISK MANAGEMENT OF MEDICAL DEVICES
        • 3.4.1.5     ISO 12807:2018 SAFE TRANSPORT OF RADIOACTIVE MATERIALS- LEAKAGE TESTING ON PACKAGES
        • 3.4.1.6     IEC 60601-1 MEDICAL ELECTRICAL EQUIPMENT STANDARD
        • 3.4.1.7     IEC 60601-1-2 ELECTROMAGNETIC COMPATIBILITY (EMC) FOR MEDICAL DEVICES
      • 3.4.2     U.S.
      • 3.4.3     CANADA
      • 3.4.4     EUROPE
      • 3.4.5     JAPAN
      • 3.4.6     CHINA
      • 3.4.7     INDIA
    • 3.5     CLINICAL TRIALS DATA
    • 3.6     PORTER’S FIVE FORCE ANALYSIS
      • 3.6.1     THREAT OF NEW ENTRANTS
      • 3.6.2     THREAT OF SUBSTITUTES
      • 3.6.3     BARGAINING POWER OF SUPPLIERS
      • 3.6.4     BARGAINING POWER OF BUYERS
      • 3.6.5     COMPETITIVE RIVALRY
    • 3.7     SUPPLY CHAIN ANALYSIS
    • 3.8     FUNDING SCENARIO
    • 3.9     MARKET SHARE ANALYSIS BY MAJOR PLAYERS
      • 3.9.1     INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE ANALYSIS
      • 3.9.2     IO ABLATION GLOBAL MARKET SHARE ANALYSIS
      • 3.9.3     IO EMBOLIZATION GLOBAL MARKET SHARE ANALYSIS
      • 3.9.4     RADIOFREQUENCY ABLATION GLOBAL MARKET SHARE ANALYSIS
      • 3.9.5     IO MICROWAVE ABLATION GLOBAL MARKET SHARE ANALYSIS
      • 3.9.6     IO TARE GLOBAL MARKET SHARE ANALYSIS
      • 3.9.7     IO DEB-TACE GLOBAL MARKET SHARE ANALYSIS
      • 3.9.8     IO TAE GLOBAL MARKET SHARE ANALYSIS
    • 3.10     INTERVENTIONAL ONCOLOGY PROCEDURE VOLUME, BASED ON PRODUCT TYPE
      • 3.10.1     IO ABLATION DEVICES UNITS PER PROCEDURE, AVERAGE SELLING PRICE, NUMBER OF PROCEDURES AND UNITS SOLD
      • 3.10.2     IO EMBOLIZATION UNITS PER PROCEDURE, AVERAGE SELLING PRICE AND NUMBER OF PROCEDURES
    • 3.11     INTERVENTIONAL ONCOLOGY NUMBER OF UNITS BASED ON REGION
      • 3.11.1     IO ABLATION DEVICES NUMBER OF UNITS BASED ON REGION
      • 3.11.2     IO RADIOFREQUENCY ABLATION DEVICES NUMBER OF UNITS BASED ON REGION
      • 3.11.3     IO MICROWAVE ABLATION DEVICES NUMBER OF UNITS BASED ON REGION
      • 3.11.4     IO CRYOABLATION DEVICES NUMBER OF UNITS BASED ON REGION
      • 3.11.5     ANALYSIS OF INTERVENTION ONCOLOGY ABLATION DEVICES BY UNIT VOLUME BASED ON COUNTRY (NOS)
  • 4     INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BASED ON PRODUCT
    • 4.1     INTRODUCTION
    • 4.2     ABLATION
      • 4.2.1     RADIOFREQUENCY ABLATION
      • 4.2.2     MICROWAVE ABLATION
      • 4.2.3     CRYOABLATION
      • 4.2.4     HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU)
      • 4.2.5     OTHER ABLATION
    • 4.3     EMBOLIZATION
      • 4.3.1     IO TRANS-ARTERIAL RADIO-EMBOLIZATION(TARE)/ SELECTIVE INTERNAL RADIATION THERAPY (SIRT)
      • 4.3.2     IO TRANSARTERIAL CHEMO-EMBOLIZATION (TACE)
      • 4.3.3     IO DRUG-ELUTING BEADS TRANSARTERIAL CHEMO-EMBOLIZATION (DEB-TACE)
      • 4.3.4     IO BLAND EMBOLIZATION/ TRANSARTERIAL EMBOLIZATION (TAE)
  • 5     INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BASED ON APPLICATION
    • 5.1     INTRODUCTION
      • 5.1.1     LIVER CANCER
      • 5.1.2     KIDNEY CANCER
      • 5.1.3     LUNG CANCER
      • 5.1.4     BRAIN AND SPINE CANCER
      • 5.1.5     PROSTATE CANCER
      • 5.1.6     OTHER APPLICATIONS
  • 6     INTERVENTIONAL ONCOLOGY GLOBAL MARKET, BASED ON END-USERS
    • 6.1     INTRODUCTION
      • 6.1.1     HOSPITALS
      • 6.1.2     AMBULATORY SURGICAL CENTERS (ASCS)
      • 6.1.3     ACADEMICS AND RESEARCH INSTITUTES
  • 7     REGIONAL ANALYSIS
    • 7.1     INTRODUCTION
    • 7.2     NORTH AMERICA
      • 7.2.1     U.S.
      • 7.2.2     REST OF NORTH AMERICA
    • 7.3     EUROPE
      • 7.3.1     GERMANY
      • 7.3.2     FRANCE
      • 7.3.3     ITALY
      • 7.3.4     REST OF E.U.
    • 7.4     APAC
      • 7.4.1     CHINA
      • 7.4.2     JAPAN
      • 7.4.3     AUSTRALIA
      • 7.4.4     REST OF APAC
    • 7.5     ROW
      • 7.5.1     BRAZIL
      • 7.5.2     REST OF LATAM
      • 7.5.3     MIDDLE EAST AND OTHERS
  • 8     MAJOR COMPANIES
    • 8.1     ANGIODYNAMICS INC.
      • 8.1.1     OVERVIEW
      • 8.1.2     FINANCIALS
      • 8.1.3     PRODUCT PORTFOLIO
      • 8.1.4     KEY DEVELOPMENTS
      • 8.1.5     BUSINESS STRATEGY
      • 8.1.6     SWOT ANALYSIS
    • 8.2     BOSTON SCIENTIFIC CORPORATION
      • 8.2.1     OVERVIEW
      • 8.2.2     FINANCIALS
      • 8.2.3     PRODUCT PORTFOLIO
      • 8.2.4     KEY DEVELOPMENTS
      • 8.2.5     BUSINESS STRATEGY
      • 8.2.6     SWOT ANALYSIS
    • 8.3     CDH INVESTMENTS (CDH GENTECH LTD), (SIRTEX LTD.)
      • 8.3.1     OVERVIEW
      • 8.3.2     FINANCIALS
      • 8.3.3     PRODUCT PORTFOLIO
      • 8.3.4     KEY DEVELOPMENTS
      • 8.3.5     BUSINESS STRATEGY
      • 8.3.6     SWOT ANALYSIS
    • 8.4     GUERBET
      • 8.4.1     OVERVIEW
      • 8.4.2     FINANCIALS
      • 8.4.3     PRODUCT PORTFOLIO
      • 8.4.4     KEY DEVELOPMENTS
      • 8.4.5     BUSINESS STRATEGY
      • 8.4.6     SWOT ANALYSIS
    • 8.5     JOHNSON & JOHNSON
      • 8.5.1     OVERVIEW
      • 8.5.2     FINANCIALS
      • 8.5.3     PRODUCT PORTFOLIO
      • 8.5.4     KEY DEVELOPMENTS
      • 8.5.5     BUSINESS STRATEGY
      • 8.5.6     SWOT ANALYSIS
    • 8.6     MEDTRONIC, PLC
      • 8.6.1     OVERVIEW
      • 8.6.2     FINANCIALS
      • 8.6.3     PRODUCT PORTFOLIO
      • 8.6.4     KEY DEVELOPMENTS
      • 8.6.5     BUSINESS STRATEGY
      • 8.6.6     SWOT ANALYSIS
    • 8.7     MERIT MEDICAL SYSTEMS, INC
      • 8.7.1     OVERVIEW
      • 8.7.2     FINANCIALS
      • 8.7.3     PRODUCT PORTFOLIO
      • 8.7.4     KEY DEVELOPMENTS
      • 8.7.5     BUSINESS STRATEGY
      • 8.7.6     SWOT ANALYSIS
    • 8.8     MONTERIS MEDICAL
      • 8.8.1     OVERVIEW
      • 8.8.2     FINANCIALS
      • 8.8.3     PRODUCT PORTFOLIO
      • 8.8.4     KEY DEVELOPMENTS
      • 8.8.5     BUSINESS STRATEGY
      • 8.8.6     SWOT ANALYSIS
    • 8.9     SIEMENS HEALTHINEERS (VARIAN MEDICAL)
      • 8.9.1     OVERVIEW
      • 8.9.2     FINANCIALS
      • 8.9.3     PRODUCT PORTFOLIO
      • 8.9.4     KEY DEVELOPMENTS
      • 8.9.5     BUSINESS STRATEGY
      • 8.9.6     SWOT ANALYSIS
    • 8.10     TERUMO CORPORATION
      • 8.10.1     OVERVIEW
      • 8.10.2     FINANCIALS
      • 8.10.3     PRODUCT PORTFOLIO
      • 8.10.4     KEY DEVELOPMENTS
      • 8.10.5     BUSINESS STRATEGY
      • 8.10.6     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 2     IO ABLATION GLOBAL PROCEDURE VOLUME, BASED ON PRODUCT TYPE, (2021-2029) (NOS)
      • TABLE 3     ANALYSIS OF IO ABLATION DEVICES FOR PROCEDURAL VOLUME BASED ON COUNTRY (NOS)
      • TABLE 4     IO ABLATION DEVICES UNITS PER PROCEDURE, AVERAGE SELLING PRICE, NUMBER OF PROCEDURES AND UNITS SOLD, BASED ON REGION, (2022) (NOS.)
      • TABLE 5     IO EMBOLIZATION GLOBAL PROCEDURE VOLUME, BASED ON PRODUCT TYPE, (2021-2029) (NO’S)
      • TABLE 6     IO EMBOLIZATION DEVICES UNITS PER PROCEDURE, AVERAGE SELLING PRICE AND NUMBER OF PROCEDURES, BASED ON REGION, (2022) (NOS)
      • TABLE 7     IO ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NOS)
      • TABLE 8     IO ABLATION DEVICES NUMBER OF UNITS, BASED ON PRODUCTS, (2021-2029) (NOS)
      • TABLE 9     RADIOFREQUENCY ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NOS)
      • TABLE 10     IO MICROWAVE ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NOS)
      • TABLE 11     IO CRYOABLATION DEVICES NUMBER OF UNITS, BASED ON REGION, (2021-2029) (NOS)
      • TABLE 12     INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON PRODUCT, (2021-2029) ($MN)
      • TABLE 13     IO ABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 14     IO ABLATION GLOBAL MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 15     IO RADIOFREQUENCY ABLATION GLOBAL MARKET REVENUE, BAESD ON REGION, (2021-2029) ($MN)
      • TABLE 16     IO MICROWAVE ABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 17     IO CRYOABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 18     IO HIFU ABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 19     IO OTHER ABLATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 20     IO EMBOLIZATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 21     IO EMBOLIZATION GLOBAL MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
      • TABLE 22     IO TARE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 23     IO TACE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 24     IO DEB-TACE GLOBAL MARKET REVENUE, BASED ON REGION,(2021-2029) ($MN)
      • TABLE 25     IO BLAND/TAE GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 26     TAE AND DEB-TACE PRODUCTS MATRIX
      • TABLE 27     INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
      • TABLE 28     IO ABLATION GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 29     IO EMBOLIZATION GLOBAL MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 30     IO LIVER CANCER APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 31     IO LIVER CANCER ABLATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 32     IO LIVER CANCER EMBOLIZATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 33     IO KIDNEY CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 34     IO LUNG CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 35     IO LUNG CANCER ABLATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 36     IO LUNG CANCER EMBOLIZATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 37     IO BRAIN & SPINE CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 38     IO PROSTATE CANCER GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 39     IO PROSTATE CANCER ABLATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 40     IO PROSTATE CANCER EMBOLIZATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 41     IO OTHER APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 42     IO OTHER ABLATION APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 43     IO OTHER EMBOLIZATON APPLICATION GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 44     INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 45     IO HOSPITALS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 46     IO AMBULATORY SURGICAL CENTERS GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 47     IO ACADEMICS AND RESEARCH INSTITUTES GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 48     INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION, (2021-2029) ($MN)
      • TABLE 49     NORTH AMERICA IO MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
      • TABLE 50     NORTH AMERICA IO ABLATION MARKET REVENUE, BASED ON PRODUCT TYPE , (2021-2029) ($MN)
      • TABLE 51     NORTH AMERICA IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
      • TABLE 52     NORTH AMERICA IO MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
      • TABLE 53     NORTH AMERICA IO ABLATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 54     NORTH AMERICA IO EMBOLIZATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 55     NORTH AMERICA IO MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 56     NORTH AMERICA IO MARKET REVENUE, BASED ON COUNTRY, (2021-2029) ($MN)
      • TABLE 57     EUROPE IO MARKET REVENUE, BASED ON PRODUCTS, (2021-2029) ($MN)
      • TABLE 58     EUROPE IO ABLATION MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 59     EUROPE IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
      • TABLE 60     EUROPE IO MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
      • TABLE 61     EUROPE IO ABLATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 62     EUROPE IO EMBOLIZATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 63     EUROPE IO MARKET REVENUE, BASED ON END-USERS, (2021-2029) ($MN)
      • TABLE 64     EUROPE IO MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
      • TABLE 65     APAC IO MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
      • TABLE 66     APAC IO ABLATION MARKET REVENUE, BASED ON PRODUCT TYPE (2021-2029) ($MN)
      • TABLE 67     APAC IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
      • TABLE 68     APAC IO MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
      • TABLE 69     APAC IO ABLATION MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
      • TABLE 70     APAC IO EMBOLIZATION MARKET REVENUE, BASED ON APPLICATION (2021-2029) ($MN)
      • TABLE 71     APAC IO MARKET REVENUE, BASED ON END USERS (2021-2029) ($MN)
      • TABLE 72     APAC IO MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
      • TABLE 73     ROW IO MARKET REVENUE, BASED ON PRODUCT (2021-2029) ($MN)
      • TABLE 74     ROW IO ABLATION MARKET REVENUE, BASED ON PRODUCT TYPE, (2021-2029) ($MN)
      • TABLE 75     ROW IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2021-2029) ($MN)
      • TABLE 76     ROW IO MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 77     ROW IO ABLATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 78     ROW IO EMBOLIZATION MARKET REVENUE, BASED ON APPLICATION, (2021-2029) ($MN)
      • TABLE 79     ROW IO MARKET REVENUE, BASED ON END-USERS (2021-2029) ($MN)
      • TABLE 80     ROW IO MARKET REVENUE, BASED ON COUNTRY (2021-2029) ($MN)
      • TABLE 81     ANGIODYNAMICS, INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) ($MN)
      • TABLE 82     ANGIODYNAMICS, INC.: TOTAL REVENUE, BY SEGMENT, (2020-2022) ($MN)
      • TABLE 83     ANGIODYNAMICS, INC.: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) ($MN)
      • TABLE 84     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q1) ($MN)
      • TABLE 85     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2020-2022) (Q1) ($MN)
      • TABLE 86     BOSTON SCIENTIFIC CORP.: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENT, (2020-2022)(Q1) ($MN)
      • TABLE 87     BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2020-2022) (Q1) ($MN)
      • TABLE 88     GUERBET: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2) ($MN)
      • TABLE 89     GUERBET: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022) (Q2) ($MN)
      • TABLE 90     GUERBET: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
      • TABLE 91     JOHNSON & JOHNSON: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) (Q2)($MN)
      • TABLE 92     JOHNSON & JOHNSON: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q2) ($MN)
      • TABLE 93     JOHNSON & JOHNSON: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) (Q2) ($MN)
      • TABLE 94     MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022) ($MN)
      • TABLE 95     MEDTRONIC, PLC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) ($MN)
      • TABLE 96     MEDTRONIC, PLC: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022) ($MN)
      • TABLE 97     MEDTRONIC, PLC: NEUROSCIENCES TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022) ($MN)
      • TABLE 98     MEDTRONIC, PLC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022) ($MN)
      • TABLE 99     MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q1) ($MN)
      • TABLE 100     MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE, BASED ON SEGMENTS, (2020-2022) (Q1) ($MN)
      • TABLE 101     MERIT MEDICAL SYSTEMS, INC: CARDIOVASCULAR TOTAL REVENUE, BASED ON SUB-SEGMENTS, (2020-2022)(Q1) ($MN)
      • TABLE 102     MERIT MEDICAL SYSTEMS, INC: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022)(Q1) ($MN)
      • TABLE 103     SIEMENS HEALTHINEERS MEDICAL SYSTEM INC.: TOTAL REVENUE AND R&D EXPENSES, (2020-2022)(Q2) ($MN)
      • TABLE 104     SIEMENS HEALTHINEERS MEDICAL SYSTEM INC.: TOTAL REVENUE, BASED ON SEGMENT, (2020-2022)(Q2) ($MN)
      • TABLE 105     SIEMENS HEALTHINEERS MEDICAL SYSTEM INC.: TOTAL REVENUE, BASED ON GEOGRAPHY, (2020-2022)(Q2) ($MN)
      • TABLE 106     TERUMO CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2019-2021) ($MN)
      • TABLE 107     TERUMO CORPORATION: TOTAL REVENUE, BASED ON SEGMENT, (2019-2021) ($MN)
      • TABLE 108     TERUMO CORPORATION: TOTAL REVENUE, BASED ON GEOGRAPHY, (2019-2021) ($MN)

      LIST OF FIGURES

      • FIGURE 1     INTERVENTIONAL ONCOLOGY GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN)
      • FIGURE 2     RESEARCH METHODOLOGY: INTERVENTIONAL ONCOLOGY GLOBAL MARKET
      • FIGURE 3     INTERVENTIONAL ONCOLOGY GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
      • FIGURE 4     INTERVENTIONAL ONCOLOGY GLOBAL MARKET: FORECASTING MODEL
      • FIGURE 5     INTERVENTIONAL ONCOLOGY GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
      • FIGURE 6     INTERVENTIONAL ONCOLOGY GLOBAL MARKET SEGMENTATION
      • FIGURE 7     INTERVENTIONAL ONCOLOGY APPLICATION MARKET SEGMENTATION
      • FIGURE 8     MARKET DYNAMICS
      • FIGURE 9     INTERVENTIONAL ONCOLOGY GLOBAL MARKET: PORTER’S ANALYSIS
      • FIGURE 10     INTERVENTIONAL ONCOLOGY: SUPPLY CHAIN ANALYSIS
      • FIGURE 11     INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS 2022 (%)
      • FIGURE 12     IO ABLATION GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 13     IO EMBOLIZATION GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2022 (%)
      • FIGURE 14     IO RADIOFREQUENCY ABLATION GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 15     IO MICROWAVE ABLATION GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 16     IO TARE GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 17     IO DEB-TACE GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 18     IO TAE GLOBAL MARKET SHARE ANALYSIS, BASED ON KEY PLAYERS, 2022 (%)
      • FIGURE 19     IO ABLATION GLOBAL PROCEDURE VOLUME, BASED ON PRODUCT TYPE, (2021-2029) (NOS)
      • FIGURE 20     IO EMBOLIZATION GLOBAL PROCEDURE VOLUME, BASED ON PRODUCT TYPE, (2021-2029) (NOS)
      • FIGURE 21     IO ABLATION DEVICES NUMBER OF UNITS, BASED ON PRODUCT, (2021-2029) (NOS)
      • FIGURE 22     IO RADIOFREQUENCY ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION (2022) (NOS)
      • FIGURE 23     IO MICROWAVE ABLATION DEVICES NUMBER OF UNITS, BASED ON REGION (2022) (NOS)
      • FIGURE 24     IO CRYOABLATION DEVICES NUMBER OF UNITS, BASED ON REGION (2022) (NOS)
      • FIGURE 25     INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 26     IO ABLATION GLOBAL MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 27     IO CRYOABLATION GLOBAL MARKET SHARE, BASED ON REGION (2022 V/S 2029) (%)
      • FIGURE 28     IO HIFU ABLATION GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
      • FIGURE 29     IO EMBOLIZATION GLOBAL MARKET SHARE, BASED ON PROCEDURE (2022 VS 2029) (%)
      • FIGURE 30     IO DEB-TACE GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
      • FIGURE 31     IO BLAND/TAE GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
      • FIGURE 32     INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE, BASED ON APPLICATION (2022 VS 2029) (%)
      • FIGURE 33     IO ABLATION GLOBAL MARKET SHARE, BASED ON APPLICATION (2022) (%)
      • FIGURE 34     IO EMBOLIZATION GLOBAL MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 35     IO PROSTATE CANCER ABLATION APPLICATION GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
      • FIGURE 36     INTERVENTIONAL ONCOLOGY GLOBAL MARKET SHARE, BASED ON END-USERS (2022 V/S 2029) (%)
      • FIGURE 37     IO HOSPITALS GLOBAL MARKET SHARE, BASED ON REGION (2022 VS 2029) (%)
      • FIGURE 38     IO GLOBAL MARKET REVENUE, BASED ON REGION (2021-2029) ($MN), CAGR (%)
      • FIGURE 39     IO GLOBAL MARKET SHARE, BASED ON REGION AND MARKET REVENUE BASED ON COUNTRY (2022) (%) ($MN)
      • FIGURE 40     NORTH AMERICA IO MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
      • FIGURE 41     NORTH AMERICA IO ABLATION MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 42     NORTH AMERICA IO EMBOLIZATION MARKET SHARE, BASED ON PROCEDURE (2022 V/S 2029) (%)
      • FIGURE 43     NORTH AMERICA IO MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 44     NORTH AMERICA IO ABLATION MARKET SHARE, BASED ON APPLICATION (2022) (%)
      • FIGURE 45     NORTH AMERICA IO EMBOLIZATION MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 46     NORTH AMERICA IO MARKET SHARE, BASED ON END-USERS (2022 V/S 2029) (%)
      • FIGURE 47     NORTH AMERICA IO MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 48     U.S. IO MARKET REVENUE, BASED ON PRODUCTS AND END USERS (2022 V/S 2029) ($MN)
      • FIGURE 49     U.S. IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 50     U.S. IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 V/S 2029) ($MN)
      • FIGURE 51     REST OF N.A. IO MARKET REVENUE BASED ON PRODUCTS & END USER (2022 VS 2029) ($MN)
      • FIGURE 52     REST OF N.A. IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 53     REST OF N.A. IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 54     EUROPE IO MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
      • FIGURE 55     EUROPE IO MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 56     EUROPE IO EMBOLIZATION MARKET SHARE, BASED ON PROCEDURE (2022 V/S 2029) (%)
      • FIGURE 57     EUROPE IO MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 58     EUROPE IO ABLATION MARKET SHARE, BASED ON APPLICATION (2022) (%)
      • FIGURE 59     EUROPE IO EMBOLIZATION MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 60     EUROPE IO MARKET SHARE, BASED ON END-USERS (2022 V/S 2029) (%)
      • FIGURE 61     EUROPE IO MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 62     GERMANY IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
      • FIGURE 63     GERMANY IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 64     GERMANY IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE & APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 65     FRANCE IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
      • FIGURE 66     FRANCE IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 67     FRANCE IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 68     ITALY IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
      • FIGURE 69     ITALY IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 70     ITALY IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 71     REST OF E.U. IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
      • FIGURE 72     REST OF E.U. IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 73     REST OF E.U. IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 74     APAC IO MARKET SHARE, BASED ON PRODUCT (2022 V/S 2029) (%)
      • FIGURE 75     APAC IO ABLATION MARKET SHARE, BASED ON PRODUCT TYPE (2022 V/S 2029) (%)
      • FIGURE 76     APAC IO EMBOLIZATION MARKET SHARE, BASED ON PROCEDURE (2022 V/S 2029) (%)
      • FIGURE 77     APAC IO MARKET SHARE, BASED ON APPLICATION (2022 VS 2029) (%)
      • FIGURE 78     APAC IO ABLATION MARKET SHARE, BASED ON APPLICATION (2022) (%)
      • FIGURE 79     APAC IO EMBOLIZATION MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 80     APAC IO MARKET SHARE, BASED ON END USERS (2022 V/S 2029) (%)
      • FIGURE 81     APAC IO MARKET SHARE, BASED ON COUNTRY (2022 V/S 2029) (%)
      • FIGURE 82     CHINA IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
      • FIGURE 83     CHINA IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 84     CHINA IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 85     JAPAN IO MARKET REVENUE, BASED ON PRODUCTS & END-USER (2022 VS 2029) ($MN)
      • FIGURE 86     JAPAN IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 V/S 2029) (%)
      • FIGURE 87     JAPAN IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 88     AUSTRALIA IO MARKET REVENUE, BASED ON PRODUCTS & END-USERS (2022 VS 2029) ($MN)
      • FIGURE 89     AUSTRALIA IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 90     AUSTRALIA IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 91     REST OF APAC IO MARKET REVENUE BASED ON PRODUCTS & END-USERS (2022 VS 2029) ($MN)
      • FIGURE 92     REST OF APAC IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 93     REST OF APAC IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 94     ROW IO MARKET SHARE, BASED ON PRODUCTS (2022 V/S 2029) (%)
      • FIGURE 95     ROW IO ABLATION MARKET SHARE, BASED ON PRODUCT TYPE (2022 VS 2029) (%)
      • FIGURE 96     ROW IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE, (2022 VS 2029) (%)
      • FIGURE 97     ROW IO MARKET SHARE, BASED ON APPLICATION (2022) (%) (% CAGR)
      • FIGURE 98     ROW IO ABLATION MARKET SHARE, BASED ON APPLICATION (2022) (%) (% CAGR)
      • FIGURE 99     ROW IO EMBOLIZATION MARKET SHARE, BASED ON APPLICATION (2022 V/S 2029) (%)
      • FIGURE 100     ROW IO MARKET SHARE, BASED ON END-USERS (2022 VS 2029) (%)
      • FIGURE 101     ROW IO MARKET SHARE, BASED ON COUNTRY (2022 VS 2029) (%)
      • FIGURE 102     BRAZIL IO MARKET REVENUE, BASED ON PRODUCTS & END-USERS (2022VS 2029) ($MN)
      • FIGURE 103     BRAZIL IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 104     BRAZIL IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 105     REST OF LATAM IO MARKET REVENUE, BASED ON PRODUCTS & END-USERS (2022 VS 2029) ($MN)
      • FIGURE 106     REST OF LATAM IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 107     REST OF LATAM IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 108     MIDDLE EAST & OTHERS IO MARKET REVENUE, BASED ON PRODUCTS & END-USERS (2022 VS 2029) ($MN)
      • FIGURE 109     MIDDLE EAST & OTHERS IO ABLATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 110     MIDDLE EAST & OTHERS IO EMBOLIZATION MARKET REVENUE, BASED ON PROCEDURE AND APPLICATION (2022 VS 2029) ($MN)
      • FIGURE 111     SWOT: ANGIODYNAMICS, INC.
      • FIGURE 112     SWOT: BOSTON SCIENTIFIC CORPORATION
      • FIGURE 113     SWOT: CDH INVESTMENTS
      • FIGURE 114     SWOT: GUERBET
      • FIGURE 115     SWOT: JOHNSON & JOHNSON
      • FIGURE 116     SWOT: MEDTRONIC, PLC
      • FIGURE 117     SWOT: MERIT MEDICAL SYSTEMS, INC.
      • FIGURE 118     SWOT: MONTERIS MEDICAL
      • FIGURE 119     SWOT: SIEMENS HEALTHINEERS MEDICAL SYSTEM INC.
      • FIGURE 120     SWOT: TERUMO CORPORATION

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     ACCUTARGET MEDIPHARMA (SHANGHAI) CO., LTD
      • 2     ANGIODYNAMICS, INC.
      • 3     BALT GROUP
      • 4     BOSTON SCIENTIFIC CORPORATION
      • 5     BVM MEDICAL LIMITED
      • 6     CHANGI JIANYUAN TECHNOLOGY DEVELOPMENT
      • 7     CLINICAL LASERTHERMIA SYSTEMS
      • 8     COOK MEDICAL
      • 9     CREO MEDICAL LTD
      • 10     DIROS TECHNOLOGY INC.
      • 11     ECO MEDICAL
      • 12     EDAP TMS
      • 13     GUERBET
      • 14     HAIFU MEDICAL
      • 15     ICE CURE MEDICAL
      • 16     IMBIOTECHNOLOGIES LTD
      • 17     INSIGHTEC
      • 18     JOHNSON & JOHNSON
      • 19     MEDTRONIC, PLC
      • 20     MEDWAVES, INC.
      • 21     MERIT MEDICAL SYSTEMS
      • 22     MIANYANG SONIC ELECTRONIC
      • 23     MONTERIS MEDICAL
      • 24     NANOSPECTRA BIOSCIENCES, INC.
      • 25     NOVIAN HEALTH, INC
      • 26     OLYMPUS CORPORATION
      • 27     PHARMACEPT GMBH
      • 28     PROFOUND MEDICAL CORPORATION
      • 29     QUANTUM SURGICAL
      • 30     RBC MEDICAL INNOVATIONS
      • 31     SCITECH MEDICAL
      • 32     SHENZHEN HUIKANG MEDICAL APPARATUS CO., LTD. (WIKKON)
      • 33     SIEMENS HEALTHINEERS (VARIAN)
      • 34     SIRTEX MEDICAL LIMITED/CDH
      • 35     SONABLATE CORP.
      • 36     STARMED CO., LTD.
      • 37     SURGNOVA HEALTHCARE TECHNOLOGIES (ZHEJIANG) CO., LTD.
      • 38     SYMPLE SURGERY
      • 39     TELEFLEX INCORPORATED
      • 40     TERUMO CORPORATION